<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488550</url>
  </required_header>
  <id_info>
    <org_study_id>ANX007-GLA-01</org_study_id>
    <nct_id>NCT03488550</nct_id>
  </id_info>
  <brief_title>Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose, Dose-escalation, Safety, Tolerability, and PK Study of Intravitreal ANX007 in Participants With Primary Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi center, open-label, single dose, safety study. Approximately 9 to 15
      participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will
      receive ANX007 administered as single, IVT injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, open-label, dose-escalation, safety study evaluating up to 3 dose levels
      of ANX007 administered as single IVT injections. Approximately 9 to 15 eligible participants
      are enrolled into one cohort each. All participants receive ANX007 in an open-label manner.
      The primary objective is to evaluate the safety and tolerability of a single intravitreal
      (IVT) injection of ANX007 in participants with primary open-angle glaucoma. Secondary
      objectives are to evaluate the serum pharmacokinetics (PK) and immunogenicity. An exploratory
      objective will evaluate the pharmacodynamic (PD) effect of ANX007 on serum C1q activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Actual">August 3, 2018</completion_date>
  <primary_completion_date type="Actual">August 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by the occurrence of adverse events</measure>
    <time_frame>Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum plasma concentration of ANX007 after a single IVT injection.</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of ANX007 after a single IVT injection.</measure>
    <time_frame>Day 56</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of a single IVT injection of ANX007 on serum C1q</measure>
    <time_frame>Day 15</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>ANX007-GLA-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ANX007</intervention_name>
    <description>Single ascending dose</description>
    <arm_group_label>ANX007-GLA-01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 18 years and older

          -  Diagnosis of primary open-angle glaucoma

          -  Intraocular pressure &lt;21 mm Hg on a stable IOP treatment regimen

          -  Reliable visual field testing

        Exclusion Criteria:

          -  BCVA worse than 20/80 in either eye

          -  Extensive glaucomatous visual-field damage

          -  History of intraocular inflammatory or infectious eye disease in study eye

          -  Ocular trauma in study eye within the preceding 6 months

          -  History of uncomplicated cataract surgery less than 6 mos prior

          -  Any abnormality preventing reliable Tonopen tonometry in study eye

          -  Active malignancy within past 5 yrs

          -  Previous tx with another humanized monoclonal antibody

          -  History of any autoimmune or neurologic disease

          -  Concurrent use of glucocorticoid medications

          -  Receiving monoamine oxidase inhibitor therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Humphriss</last_name>
    <role>Study Director</role>
    <affiliation>Annexon Vice President of Clinical Operations</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.annexonbio.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

